NCCN Ovarian Cancer Guidelines Add Options for PARP Inhibitors, Bevacizumab

A presentation Saturday at the National Comprehensive Cancer Network Annual Conference in Orlando, Florida, outlined several key updates for treatment in ovarian cancer based on new studies and approvals for poly (ADP-ribose) polymerase (PARP) inhibitors and bevacizumab.

Read the full article here

Related Articles